Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression
Alam, S. K.; Pandit, A.; Wang, L.; Thiele, B. A.; Manoj, P.; Aubry, M. C.; Rudin, C. M.; Lo, Y.-C.; Hoeppner, L. H.
Show abstract
Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents. Here, we show that treatment with a dopamine D2 receptor (D2R) agonist reduces tumour angiogenesis in multiple in vivo xenograft models of human SCLC, thereby reducing SCLC progression. An FDA-approved D2R agonist, cabergoline, also sensitized chemoresistant SCLC tumours to cisplatin and etoposide in patient-derived xenograft models of acquired chemoresistance in mice. Ex vivo, D2R agonist treatment decreased tumour angiogenesis through increased apoptosis of tumour-associated endothelial cells, creating a less favourable tumour microenvironment that limited cancer cell proliferation. In paired SCLC patient-derived specimens, D2R was expressed by tumour-associated endothelial cells obtained before treatment, but D2R was downregulated in SCLC tumours that had acquired chemoresistance. D2R agonist treatment of chemotherapy-resistant specimens restored expression of D2R. Activation of dopamine signalling is thus a new strategy for inhibiting angiogenesis in SCLC and potentially for combatting chemotherapy-refractory SCLC progression.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer 95%
- Ddr1-Induced Neutrophil Extracellular Traps Drive Pancreatic Cancer Metastasis 94%
- The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids 93%
Similar papers in this journal
- FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer 95%
- Epigenomic profiling discovers trans-lineage SOX2 partnerships driving tumor heterogeneity in lung squamous cell carcinoma 93%
- A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer 93%
Similar papers in this journal
- Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma 95%
- Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes 94%
- GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer 94%
Similar papers in this journal
- ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumor cell survival 97%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 94%
- Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer 93%
Similar papers in this journal
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 93%
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 93%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.